AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00476970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
Study NCT03350919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training in the intact field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
Study NCT01032928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory-Swallow Phase training
Description: Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
Study NCT01850316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
Study NCT03173274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
Study NCT03173274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention
Description: Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
Study NCT03173274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingent Reinforcement for negative breath CO samples
Study NCT03173274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contingent Reinforcement
Description: Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value \[CM control\]
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass testing using RDTs
Description: To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mass testing using RDTs
Description: To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.
Study NCT04301531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment for all cases confirmed positive malaria cases with ACTs
Description: During each mass testing, all confirmed positive cases are treated in both arms.
Study NCT04301531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment for all cases confirmed positive malaria cases with ACTs
Description: During each mass testing, all confirmed positive cases are treated in both arms.
Study NCT01096940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet, BID dose
Study NCT01096940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Oral tablet, single dose
Study NCT05563324 — intervention group
Intervention type: GENETIC
Intervention: DNA extraction and genotyping of candidate genetic polymorphisms
Study NCT05563324 — intervention group
Intervention type: OTHER
Intervention: self-assessment questionnaires
Study NCT00911911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
Study NCT00911911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BIOPSY
Description: Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
Study NCT00911911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SURGERY
Description: Surgery after neoadjuvant chemotherapy
Study NCT03146390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essential oils
Description: all subjects will perform all interventions of all arms
Study NCT03146390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol free essential oils
Description: all subjects will perform all interventions of all arms
Study NCT03146390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: all subjects will perform all interventions of all arms
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 0.5 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 1.5 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 5 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 15 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 50 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 100 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 200 mg QD IV x 1 day
Study NCT01285518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, USP QD IVx 1 day
Study NCT03713918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reinforced lithium silicate endocrowns
Description: The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
Study NCT03713918 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post retained reinforced lith silicate crn
Description: The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
Study NCT02244632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modufolin (arfolitixorin)
Description: IV injection every second week for 8 weeks.
Study NCT02244632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: IV injection every second week for 8 weeks.
Study NCT02244632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion every second week for 8 weeks.
Study NCT02244632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion every second week for 8 weeks.
Study NCT02244632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion every second week for 8 weeks.
Study NCT01764841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI (BAYQ3939)
Description: Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Study NCT01764841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Study NCT02016326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Colon
Description: High Definition White Light
Study NCT02016326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-scan 1
Description: I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
Study NCT02016326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan 2
Description: I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
Study NCT00797758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord blood transplantation
Description: Umbilical cord blood transplantation after reduced intensity conditioning
Study NCT01528371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started.
Study NCT01528371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution (NSS)
Description: 1. Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~2. Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~3. Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~4. 10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~5. Investigators inject an additional sedative agent and the dental treatment is started.
Study NCT03040726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant
Description: Given PO
Study NCT03040726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Given PO
Study NCT03040726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: Given PO
Study NCT03040726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03040726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03040726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03962361 — intervention group
Intervention type: OTHER
Intervention: Concentration of circulating microparticles.
Description: The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
Study NCT02475369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pancrelipase
Study NCT01092767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft with the Captivia Delivery System
Description: All subjects will be implanted with this device
Study NCT02243657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of Hb
Description: Hb of all children in the subgroup study are measured using a haemocure photometer.
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of Hb
Description: Hb of all children in the subgroup study are measured using a haemocure photometer.
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household survey
Description: Determine the prevalence of febrile illnesses among children in the subgroup study
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Household survey
Description: Determine the prevalence of febrile illnesses among children in the subgroup study
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-base management of malaria
Description: Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
Study NCT04301531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Community-base management of malaria
Description: Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
Study NCT00239551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevacid
Description: Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 \& EGD with biopsy at 8 weeks
Study NCT04836403 — intervention group
Intervention type: OTHER
Intervention: Sinus and nasal quality of life survey questionnaire (SN-5)
Description: The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)
Study NCT03023761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser
Description: low level laser irradiation
Study NCT03023761 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser sham
Description: laser without irradiation
Study NCT00322543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corio™ Pimecrolimus-eluting stent
Study NCT02951689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT02243657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02938663 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires and Measurements
Description: Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
Study NCT01242982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed reduction and fixation with 2 pins
Description: Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
Study NCT01242982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction and Plaster of Paris
Description: Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
Study NCT00909467 — intervention group
Intervention type: OTHER
Intervention: echocardiography, right heart catheterisation
Description: at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
Study NCT04773132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein
Description: Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
Study NCT01865019 — intervention group
Intervention type: DEVICE
Intervention: mechanical ventilation
Study NCT03462680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: niacin
Description: Niacin or nicotinic acid 250 mg tablets
Study NCT03462680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study NCT01470534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate drink
Description: carbohydrate drink
Study NCT01470534 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle biopsy
Description: Open muscle biopsy
Study NCT01470534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Open muscle biopsy
Study NCT02951689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04492800 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Paxman Scalp Cooling Device
Description: Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
Study NCT01470534 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Venopuncture
Study NCT01470534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Venopuncture
Study NCT01470534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00912262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Liquid
Study NCT04278222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Toripalimab
Description: Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
Study NCT02874417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAST psychoeducation
Study NCT02874417 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PHET
Study NCT03114800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Scale
Description: The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
Study NCT03805087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial coil embolization
Description: Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
Study NCT02316327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, cisplatin and bevacizumab
Description: Therapeutic
Study NCT01639560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
Study NCT01639560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
Study NCT03959410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical biopsy
Description: in office Cervical biopsy
Study NCT04501211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Granisetron
Description: transdermal sancuso patch
Study NCT03909529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 250 MCG Oral Tablet
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Study NCT03909529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/ 5 mL S/F Suspension
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Study NCT02234973 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality Improvement
Description: Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.